This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Emerging Treatments in Schizophrenia Video

Christoph U. Correll, Anissa Abi-Dargham, and Oliver Howes

Published: February 17, 2022

Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.

Read the InfoPack

Quick Links: Psychopharmacology , Schizophrenia and Schizoaffective Disorders


Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial

First-episode schizophrenia patients with suicidal ideation and substance use disorder are often excluded from clinical trials. Omitting...